Home   |   About Us   |   News & Features   |   Peptide Products   |   R & D   |   Reputations   |   Media Focus   |   Peptide Museum   |   Case Study
 
 
  Home > News & Features
--Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells
2012-11-23

 

Nature Medicine

The BTB/POZ transcriptional repressor and candidate oncogene BCL6 is frequently misregulated in B-cell lymphomas. The interface through which the BCL6 BTB domain mediates recruitment of the SMRT, NCoR and BCoR corepressors was recently identified. To determine the contribution of this interface to BCL6 transcriptional and biological properties, we generated a peptide that specifically binds BCL6 and blocks corepressor recruitment in vivo. This inhibitor disrupts BCL6-mediated repression and establishment of silenced chromatin, reactivates natural BCL6 target genes, and abrogates BCL6 biological function in B cells. In BCL6-positive lymphoma cells, peptide blockade caused apoptosis and cell cycle arrest. BTB domain peptide inhibitors may constitute a novel therapeutic agent for B-cell lymphomas.

 
Copyright @ 2003-2007 China Peptide Valley. All rights reserved
Wuhan Jiushengtang Bioengineering Co.,Ltd.,the world's earliest, largest and best professional enzymatic peptide nutraceutical company committed to helping people improve their health by discovering and developing peptide supplement.